FRI0310 Achievement of low disease activity in lupus patients treated with belimumab is independent of serologic status at baseline: a real-life observational study

Antonis Fanouriakis ,Pinelopi Konstantopoulou ,George Βertsias ,S.-N Liossis ,Anastasia Klagou ,P Sfikakis ,Styliani Konsta ,Sofia Koutsoviti ,Chrysanthi Staveri ,C P Mavragani ,Antonia Elezoglou ,Despoina Dimopoulou ,Lamprini Pantazi ,Kyriaki Boki ,Stella Ntali ,Christina Tsalapaki ,Demetrios Vassilopoulos ,Georgios Katsikas ,Maria G Tektonidou ,Abdülsamet Erden ,Christina Adamichou ,Prodromos Sidiropoulos ,Stylianos Panopoulos ,Dt Boumpas

doi:10.1136/annrheumdis-2018-eular.5259

Abstract

BackgroundLow disease activity is a validated target of systemic lupus erythematosus (SLE) therapy.Objectivesτo assess the ability of belimumab to induce low disease activity states in real-life setting.MethodsMulticentre prospective observational study...

Full Text